Related Experiment Video

Updated: Jun 24, 2025

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
12:38

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

2.5K

Studies on the mechanisms of action of MR33317

Joachim Neumann1, C Hesse2, S Yahiaoui3

  • 1Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 4, 06097, Halle (Saale), Germany. joachim.neumann@medizin.uni-halle.de.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|June 10, 2024
PubMed

Insights

MR33317 acts as a 5-HT4 receptor agonist in the heart, potentially treating Alzheimer's disease. However, this action may increase the risk of atrial fibrillation.

Area of Science:

  • Pharmacology
  • Cardiology
  • Neuroscience

Background:

  • MR33317 is an acetylcholinesterase inhibitor and a brain 5-HT4 receptor agonist with potential Alzheimer's disease therapeutic applications.
  • Its therapeutic effects may stem from dual synergistic activity.
  • The study investigated MR33317's activity at cardiac 5-HT4 receptors.

Purpose of the Study:

  • To determine if MR33317 stimulates 5-HT4 receptors in the heart.
  • To evaluate the functional effects of MR33317 on cardiac contractility and rate.
  • To assess the potential clinical implications of MR33317's cardiac activity.

Main Methods:

  • Testing MR33317 on isolated mouse atrial preparations with and without cardiac 5-HT4 receptor overexpression.
  • Assessing MR33317's effect on force of contraction and beating rate in human atrial preparations, with and without cilostamide.
  • Investigating the effect of tropisetron and GR125487 on MR33317-induced contractility changes in human atria.

Main Results:

  • MR33317 increased atrial contraction and beating rate in 5-HT4 receptor-overexpressing mice, but not in wild-type mice.
  • In human atria, MR33317 increased force of contraction only when combined with cilostamide (a PDE III inhibitor).
  • This effect in human atria was inhibited by tropisetron and GR125487, confirming MR33317 as a 5-HT4 receptor agonist.

Conclusions:

  • MR33317 acts as an agonist at human cardiac 5-HT4 receptors.
  • The drug's cardiac effects, particularly in conjunction with phosphodiesterase III inhibition, suggest a potential for inducing atrial fibrillation in clinical use.
Keywords:
5-HT4-receptorsHuman atriumMR33317Transgenic mice

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

13.5K

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
432
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
554